Royce & Associates LP Boosts Stock Holdings in LifeMD, Inc. (NASDAQ:LFMD)

Royce & Associates LP lifted its stake in shares of LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 14.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 901,041 shares of the company's stock after purchasing an additional 114,710 shares during the period. Royce & Associates LP owned about 2.09% of LifeMD worth $4,721,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in LifeMD by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company's stock worth $11,875,000 after purchasing an additional 128,701 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of LifeMD by 15.1% in the second quarter. Cubist Systematic Strategies LLC now owns 551,344 shares of the company's stock valued at $3,782,000 after purchasing an additional 72,203 shares during the last quarter. Bank of New York Mellon Corp lifted its position in LifeMD by 63.6% during the second quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company's stock worth $1,609,000 after buying an additional 91,183 shares in the last quarter. Squarepoint Ops LLC boosted its stake in LifeMD by 23.8% during the second quarter. Squarepoint Ops LLC now owns 154,390 shares of the company's stock worth $1,059,000 after buying an additional 29,692 shares during the last quarter. Finally, Ancora Advisors LLC grew its holdings in LifeMD by 97.8% in the 1st quarter. Ancora Advisors LLC now owns 137,760 shares of the company's stock valued at $1,416,000 after buying an additional 68,110 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LFMD has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. HC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of LifeMD in a research report on Monday, November 11th. Finally, B. Riley began coverage on shares of LifeMD in a research report on Friday, August 23rd. They issued a "buy" rating and a $11.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $12.00.

LifeMD Trading Up 5.7 %

Shares of LFMD stock traded up $0.30 on Tuesday, hitting $5.56. The stock had a trading volume of 458,996 shares, compared to its average volume of 745,289. The company's 50 day moving average price is $5.01 and its 200-day moving average price is $6.24. LifeMD, Inc. has a 1 year low of $3.99 and a 1 year high of $12.88. The firm has a market capitalization of $240.81 million, a P/E ratio of -8.69 and a beta of 1.23. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.